A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia
A Double-Blind Efficacy and Safety Study of Evacetrapib Followed by an Open-Label Extension in Japanese Patients With Primary Hypercholesterolemia
Sponsor: Eli Lilly and Company
Terminated
Study termination due to insufficient efficacy.
Other terminated trials from Eli Lilly and Company
This PHASE3 trial investigates Hypercholesterolemia and is currently terminated or withdrawn. Eli Lilly and Company leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Nov 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .